AC
BLUE

AXQ Capital’s bluebird bio BLUE Stock Holding History

AXQ Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-791
Closed -$50.3K – 308
2023
Q1 		$50.3K Buy
791
+222
+39% +$25.4K 0.02% 464
2022
Q4 		$78.7K Buy
+569
New +$80.2K 0.05% 306

Other funds holding BLUE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

AXQ Capital's BLUE Position: Q2 2023 in Review

AXQ Capital sold out of bluebird bio (BLUE) in Q2 2023, closing a stake of 791 shares — an estimated $50.3K sold.

AXQ Capital first reported a position in BLUE in Q4 2022 and held it in 2 quarters. The position peaked at $78.7K in Q4 2022. 175 funds tracked by Wall St. Rank hold BLUE as of Q2 2023.

  • AXQ Capital reported no remaining bluebird bio position as of Q2 2023 after selling out during the quarter.
  • AXQ Capital sold 791 bluebird bio shares in Q2 2023, an estimated $50.3K.
  • AXQ Capital first reported a position in bluebird bio in Q4 2022 and held it in 2 quarters.
  • AXQ Capital's bluebird bio position peaked at $78.7K in Q4 2022.
  • 175 funds tracked by Wall St. Rank held bluebird bio as of Q2 2023.

Based on AXQ Capital's 13F filing for Q2 2023, filed 11 Aug 2023.